Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy

Saitta, Carlo; Musolino, Cristina; Marabello, Grazia; Martino, Daniela Di; Leonardi, Maria Silvana; Pollicino, Teresa; Altavilla, Giuseppe; Raimondo, Giovanni

doi:10.1016/j.dld.2013.01.022

Cited by 19 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instead, the studies on HBV reactivation in patients with OBI are not conclusive, but so far no evidence of reactivation of OBI in these patients has emerged. The longitudinal study by Saitta et al [88] on 44 HBsAg-negative patients with solid tumors undergoing chemotherapy did not find cases with HBV reactivation. Further prospective studies are needed to improve our knowledge of the clinical importance of OBI in patients with solid cancers.…”

Section: Solid Cancersmentioning

confidence: 99%

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

Sagnelli

Pisaturo

Martini

et al. 2014

WJH

View full text Add to dashboard Cite

Section: Solid Cancersmentioning

confidence: 99%

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

Sagnelli

Pisaturo

Martini

et al. 2014

WJH

View full text Add to dashboard Cite

“…Saitta et al evaluated 44 solid tumor patients with occult HBV infection prospectively during chemotherapy period and HBV reactivation was not reported in any of these patients. 29 In our study, occult HBV infection was detected in one patient (5.9%) in group II (isolated total antiHBc positivity), HBV reactivation or hepatitis was not observed in clinical follow-up of this patient who was started lamivudine prophylaxis.…”

Section: Discussionmentioning

confidence: 83%

Follow-up of the Chronic HBV Infected Patients Planned Chemotherapy Due to Solid Organ Malignancy

Malignancy¹,

Erdem²,

Pullukçu³

et al. 2017

UHOD

View full text Add to dashboard Cite

The aim of this study was to screen the patients with solid organ malignancy for HBV (Hepatitis B virus) infection before the start of chemotherapy and follow up in the oncology department of our setting. All cases admitted to oncology department for chemotherapy were screened prospectively for HBV infection and reactivation between March 2013-September 2014. A total of 225 patients were included in the study and divided into 3 groups; Group I: having recovered past HBV infection: 43 patients (19.1%), Group II: isolated Anti-HBcAg total positive: 20 patients (8.9%) and Group III: chronic HBV infection with 10 patients (4.4%). HBV reactivation developed in one (5.9%) of 17 patients in group II, and two (28.6%) of seven patients in group III while under lamivudine prophylaxis. Neither hepatitis flare by HBV reactivation nor HBV-related death were observed in our study. In the moderate endemicity areas like Turkey for HBV infection, all patients must be screened for HBV before starting of chemotherapy.

show abstract

“…In this context, it has to be considered that patients with OBI longitudinally followed very often show phases of negativity for serum HBV DNA alternating with phases - or single time points - in which low amounts of HBV DNA are detected. This fluctuating profile has been observed in immunocompetent individuals [37,38] as well as in patients with solid tumors under chemotherapy; both conditions are usually not followed by clinically relevant viral reactivation [32]. Of note, it has recently been reported that OBI patients with detectable traces of HBV DNA before immunosuppressive therapy have comparable risks of clinical/virological reactivation as HBV-DNA-negative subjects [36].…”

Section: Obi Reactivation: Predisposing Conditions and Possible Predimentioning

confidence: 99%

“…Finally, the real risk of OBI reactivation in patients with solid tumor undergoing chemotherapy is debatable [32], and there are no reliable data available about OBI reactivation in other categories of patients, such as individuals with psoriasis, in whom treatments with biological agents are applied.…”

Section: Obi Reactivation: Predisposing Conditions and Possible Predimentioning

confidence: 99%

Therapy of Occult Hepatitis B Virus Infection and Prevention of Reactivation

Raimondo¹,

Filomia²,

Maimone³

2014

Intervirology

Self Cite

View full text Add to dashboard Cite

Occult hepatitis B virus infection (OBI) is highly prevalent worldwide. In some cases, it is a consequence of infection with variant viruses mutated in the S gene and producing a surface antigen not recognized by diagnostic kits. In most cases, OBI is due to a strong inhibition of hepatitis B virus (HBV) activities exerted by host defense mechanisms. OBI may reactivate in patients undergoing immunosuppressive therapy and/or chemotherapy with the possibility of a consequent development of acute hepatitis that may lead to hepatic failure. Hematological malignancies and therapeutic schedules including rituximab are the conditions most frequently associated with OBI reactivation. However, this event may occur in a large number of additional clinical and therapeutic settings. Identification of patients prone to undergo reactivation is of great importance for promptly starting a proper antiviral therapy that may stop the HBV reactivation and prevent its clinical sequelae.

show abstract

Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy

Cited by 19 publications

References 20 publications

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

Follow-up of the Chronic HBV Infected Patients Planned Chemotherapy Due to Solid Organ Malignancy

Therapy of Occult Hepatitis B Virus Infection and Prevention of Reactivation

Contact Info

Product

Resources

About